Breyanzi Archives -

Gilead Sciences’ Kite Pharma has become the first drugmaker to get FDA approval to use a CAR-T therapy

Gilead beats BMS to FDA okay for early lymphoma CAR-T therapy

https://pharmaphorum.com/news/gilead-beats-bms-to-fda-okay-for-early-lymphoma-car-t-therapy/

A pair of trials have suggested that CAR-T therapies could offer an improved option for patients with large

ASH: Gilead, BMS CAR-Ts square off in relapsed lymphoma

https://pharmaphorum.com/news/ash-gilead-bms-car-ts-square-off-in-relapsed-lymphoma/

Bristol-Myer Squibb has only just won FDA approval for its CAR-T Breyanzi in large B-cell lymphoma (LBCL), but

BMS will file for earlier-line use of Breyanzi in lymphoma after trial win

https://pharmaphorum.com/news/bms-will-file-for-earlier-line-use-of-breyanzi-in-lymphoma-after-trial-win/

Bristol-Myers Squibb finally has FDA approval for its CAR-T therapy liso-cel, which has been cleared by the US

BMS finally gets FDA OK for liso-cel, sets $410k launch price

https://pharmaphorum.com/news/bms-finally-gets-fda-ok-for-liso-cel-sets-410k-launch-price/

Breyanzi